Stay up to date with the latest clinical and evaluation data
Browse below for posters and presentations from recent conference appearances
Mycoplasma genitalium: macrolide resistance among a 2016-2017 cohort of patients in Barcelona, Spain.
Fernández-Huerta M et al IUSTI Europe (Helsinki) 2017
Detection of Mycoplasma genitalium macrolide resistant strains in patients attending a genitourinary medicine (GUM) clinic in Northern Ireland
McKenna JP et al IUSTI Europe (Helsinki) 2017
200 specimens collected in cobas® PCR media (swabs: rectal/vaginal, urine) from symptomatic patients, extracted on MagNA Pure 96. Tested with ResistancePlus MG for combined detection of Mycoplasma genitalium and azithromycin resistance markers. Also tested for CT/NG with commercial multiplex. Positive rates MG: 9%, CT: 4%, NG: 1.5%. Macrolide resistance found in 44% of MG positive patients.
High levels of Mycoplasma genitalium antibiotic resistance are observed in Australia
Bone S et al EMMD (Noordwijk) 2017
1089 prospective samples from symptomatic and asymptomatic patients. Tested with ResistancePlus MG for combined detection of Mycoplasma genitalium and azithromycin resistance markers, compared with in-house qPCR and sequencing. MG prevalence of 6% with 63.1% resistance. Sensitivity and specificity of MG detection (98.5%, 100%) and azithromycin resistance (100%, 96.2%).
SpeeDx PlexPCR™ VHS Evaluation
Vipond et al IUSTI (Helsinki) 2017
373 genital and non -genital swab samples extracted with QIAsymphony SP, amplified on 7500 Fast. Tested with PlexPCR VHS for combined detection of common causes of lesions (HSV-1 & 2, Treponema pallidum, and VZV) compared with in-house qPCR assays. Prevalence HSV-1 24%, HSV-2 21.3%, Syphilis 1.7% VZV 0.3%. Sensitivity and specificity of 96-100% across targets.
Multiplex assay for the detection of syphilis and other pathogens associated with genital lesions using PlexPCR®
Windsor et al IUSTI World (Rio) 2017
104 retrospective samples including genital/non-genital swabs and CSF. Tested with PlexPCR VHS for combined detection of common causes of lesions (Herpes simplex virus-1 & 2, Treponema pallidum, and Varicella zoster virus) and compared with in-house qPCR assays. Sensitivity and specificity 94-100% across targets.
Clinical Prospective Study comparing In-house Respiratory Viral Assays With a Highly Multiplexed Commercial Assay developed by SpeeDx
Nair et al ECMID (Vienna) 2017
204 clinical samples tested with development respiratory virus multiplex assay for combined detection of 11 viruses (Influenza A, Influenza B, Respiratory Synctial Virus A&B, Rhinovirus, Human Parainfluenza 1-4, Human Metapneumovirus, Adenovirus B&C) and compared with in-house qPCR assays.